AQR Capital Management
EIGR

AQR Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

AQR Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,522
Closed -$175K – 2311
2023
Q1 		$175K Sell
6,522
-9,655
-60% -$449K ﹤0.01% 2069
2022
Q4 		$573K Buy
+16,177
New +$1.94M ﹤0.01% 1758
2020
Q4 		– Sell
-828
Closed -$202K – 2279
2020
Q3 		$202K Sell
828
-911
-52% -$283K ﹤0.01% 2057
2020
Q2 		$501K Buy
1,739
+33
+2% +$9.73K ﹤0.01% 1746
2020
Q1 		$348K Buy
+1,706
New +$544K ﹤0.01% 1714
2015
Q2 		– Sell
-32
Closed -$269K – 2269
2015
Q1 		$269K Buy
+32
New +$280K ﹤0.01% 1922

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

AQR Capital Management's EIGR Position: Q2 2023 in Review

AQR Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 6,522 shares — an estimated $175K sold.

AQR Capital Management first reported a position in EIGR in Q1 2015 and held it in 6 quarters. The position peaked at $573K in Q4 2022. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

  • AQR Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • AQR Capital Management sold 6,522 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $175K.
  • AQR Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 6 quarters.
  • AQR Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $573K in Q4 2022.
  • 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on AQR Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.